SGLT2 Inhibitors in Patients with Diabetes and Cardiovascular Disease

Presenter Information

Cristina Calogero, MD, Thomas Jefferson UniversityFollow
Jillian Cooper, MD, Thomas Jefferson UniversityFollow
Mathew Francis, MD, Thomas Jefferson UniversityFollow
Joseph Grogg, MD, Thomas Jefferson UniversityFollow
Shuwen Lin, MD, Thomas Jefferson UniversityFollow
Patrick Prior, MD, Thomas Jefferson UniversityFollow
Bo Hyung Yoon, MD, Thomas Jefferson UniversityFollow
Yair Lev, MD, Thomas Jefferson UniversityFollow

Start Date

5-28-2020 7:30 AM

End Date

5-28-2020 8:30 AM

Description

Problem Definition: Multiple studies (e.g. EMPA-REG, CANVAS) demonstrate that SGLT2 Inhibitors (Inh) improve cardiac outcomes in patients with Type II Diabetes (DM2) with comorbid Cardiovascular Disease (CVD) including Heart Failure and Coronary Artery Disease. SGLT2 Inhibitors are considered standard of care for patients with DM2 and CVD. Based on literature published in European Journal of Preventative Cardiology and JACC HF, our prediction is that physicians at Thomas Jefferson University Hospital Ambulatory Practices (TJUH) under-utilize SGLT2 Inh for patients with co-morbid CVD and DM2.

Aims for Improvement: Within the Jefferson Healthcare System, we sought to determine: Future Interventions

1. The percentage of patients with an indication for an SGLT2 Inhibitor who were actually being prescribed this.
2. How often providers within the Jefferson system were prescribing these medications, and what the barriers to prescribing are. With this information, we hoped to increase the percentage of (qualifying) patients who are on these medications as part of standard of care by 20% within one year of intervention.

Comments

Presented at the 2020 House Staff Quality Improvement and Patient Safety Conference